TrialThe Journal of infectious diseases2025

A Viroimmunologic Model to Characterize the Antiviral Effect of Molnupiravir in Outpatients Infected With SARS-CoV-2: Implication for Treatment Duration.

Bach Tran Nguyen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.